A Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients with Pulmonary Sarcoidosis
-
- STATUS
- Recruiting
-
- participants needed
- 2
Summary
This study is being done to learn more about the safety of an investigational drug called ATYR1923, and to find out more about the effects of different doses of this drug on the lungs of people who have pulmonary sarcoidosis. "Investigational" means that it is not approved by the United States Food and Drug Administration. Participants will be assigned at random to receive either the study drug or placebo. A placebo is a harmless inactive substance. The study drug/placebo is given over 60 minutes intravenously (in your vein). Participation will last about 6 months and requires about 12 visits to Penn.
FAQ
Details
| Condition | sarcoidosis |
|---|---|
| Age | 18years - 93years |
| Clinical Study Identifier | TX6260 |
| Last Modified on | 19 February 2024 |
Eligibility
How to participate?
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.